Alzheimers Disease Diagnostic Market

Alzheimer's Disease Diagnostic Market Research, 2032

The Alzheimer's Disease Diagnostic Market size was USD 3.3 billion in 2021 and projected to grow from USD 4.0 billion in 2023 to USD 9.6 billion by 2032, exhibiting a CAGR of 10.2% during the forecast period

Alzheimer's is a brain illness that gradually impairs thinking and memory abilities as well as the ability to do even the most basic tasks. Growing age is the key known risk aspect for the said disease. Alzheimer's is diagnosed by doctors using a patient's mental status tests, medical history, neurological and physical examinations, diagnostic tests, and brain imaging. The illness is the most typical cause of dementia in elderly people.

Market Highlights

The Alzheimer's Disease Diagnostic Market is expected to project a CAGR of 10.2% during the forecast period, 2022-2032

Alzheimers Disease Diagnostic Market is expected to reach USD 9.6 billion, growing at a CAGR of 10.2% during the forecast period owing to increasing number of chronic illnesses like dementia, rising pipeline medicine development, and funding in biomarkers for development of drugs. The expanding treatment choices and better diagnostic procedures for the early discovery of chronic illnesses is another major driver for the growth of the Alzheimers Disease Diagnostic Market.

Alzheimers Disease Diagnostic Market Segmentation

Early Onset Alzheimers segment is expected to dominate in the forecast period

Alzheimers Disease Diagnostic Market is classified based on the Type into Early Onset Alzheimers, Late Onset Alzheimers, Familial Alzheimers Disease, and Others. The Early Onset Alzheimers segment registered a major market share in 2022 and will continue to lead over the forecast period. This is supported by the increasing demand for diagnostic testing to identify Alzheimer's at an early stage.

PET segment is expected to dominate in the forecast period

Alzheimers Disease Diagnostic Market is classified based on the Diagnostic Test into PET, SPECT, Blood based ELISA Test, CSF Assays, and Others. PET diagnostic test segment is anticipated to lead the market over the estimated period. PET is a nuclear molecular imaging method that uses radiopharmaceuticals (tracers) that have been marked using an isotope which emits positron to help visualize in vivo cellular metabolism. The approach determines the speed of uptake of these radiotracers in specifically selected cells throughout the body of a patient by detecting the positrons released during the radiotracer decay. The use of PET is crucial in the treatment of Alzheimer's disease.

Market Dynamics                                                   

Growth Drivers

The global rise in chronic illnesses and improvements in the diagnostics and detection of Alzheimer's disease are expected to boost market growth

Growth in chronic illnesses like dementia on the global scale and the efforts for drug development for a complete cure and therapy are the main factors driving the Alzheimer's Disease Diagnostic Market. The contribution of technical advancements to the improvement of detection and diagnosis of the disease is another factor impacting the market. Furthermore, another factor propelling the Alzheimers Disease Diagnostic Market is the advancement of mature diagnostics for early detection.

Number of Government Initiatives and Funding by Institutions for R&D are Expected to Boost the Market Growth

Research and development efforts to find the primary treatment for Alzheimers are receiving significant funding from government programs, medical, and academic institutions. The Alzheimers Disease Diagnostic Market is expected to grow over the projected period due to increasing pathological investigations and clinical studies with research and development.

Restrict

Lengthy clinical trials and huge investments with risk of failure may restrict market growth

The lengthy clinical trials and clearances by the medical experts are the main barrier impeding the growth of the market. Large investments and the possibility of failure might also restrain the industry growth.

Recent Developments

• The US Food and Drug Administration (FDA) granted Biogen & Eisai Co. a biological license in 2021 for a treatment called Aducanumab, which is monitored for the purpose of treating and curing Alzheimer's disease

• The Alzheimer's diagnosis, surveillance, and treatment will be the focus of a collaboration agreement signed by Eli Lilly & business with the life sciences business Quanterix in March 2022.

Key Players Covered:

• Johnson & Johnson
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Pfizer Inc.
• Merck & Co.
• GE Healthcare
• AbbVie
• Eli Lilly and Company
• Daiichi Sankyo
• Sysmex
• Quanterix
• Alector LLC
• Corium Inc
• TauRx Therapeutics
• Cognition Therapeutics Inc
• Other Prominent Players ( Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Developments, Regional Presence, SWOT Analysis )

Regional Analysis

The Alzheimer's Disease Diagnostic Market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America held the largest market share and is expected to expand rapidly throughout the projection period due to the rising prevalence of Alzheimer's disease and the significance of disease diagnostics in the region. Considerable technological improvements, particularly in the US, and the growing elderly population are the main factors affecting the region's growth in the global market. Furthermore, the advancement of the Alzheimer's Disease Diagnostic Market in general is greatly influenced by the availability of cutting-edge tools for drug discovery in the area

Alzheimers Disease Diagnostic Market is further segmented by region into:

• North America Market Size, Share, Trends, Opportunities, YoY Growth, CAGR – United States and Canada
• Latin America Market Size, Share, Trends, Opportunities, YoY Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
• Europe Market Size, Share, Trends, Opportunities, YoY Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey, and Rest of Europe
• Asia Pacific Market Size, Share, Trends, Opportunities, YoY Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
• Middle East and Africa Market Size, Share, Trends, Opportunities, YoY Growth, CAGR – North Africa, Israel, GCC, South Africa, and Rest of MENA

Alzheimers Disease Diagnostic Market Scope and Segments:

Frequently Asked Questions (FAQ):